The EVI-1 gene encodes a Zn finger, DNA binding protein preous leukemias (AML) and patients with myelodysplasia viously detected in some acute myelogenous leukemias (AML) (MDS). [7] [8] [9] [10] In some AML patients, EVI-1 expression is associa- entiation of myeloid cells.
Introduction Methods
The EVI-1 gene was originally detected as a consistent inserCell culture tion site in retrovirus-induced, experimental murine leukemias, 1, 2 and is a member of the large family of nuclear Zn Factor-dependent UCSD/AML1 cells which have a 3q26 transfinger, DNA binding proteins. 3, 4 EVI-1 protein has two zinc location and express the EVI-1 gene 11 and AML-193 cells finger DNA binding domains and an acidic domain at its carwere maintained in RPMI 1640 medium with 5% fetal bovine boxyl terminal. The first zinc finger domain contains seven serum (FBS) and 100 U/ml rhGM-CSF (recombinant human zinc fingers and binds to a consensus sequence GA(T/C)-granulocyte-macrophage colony-stimulating factor) as AAGATAAGATAA, whereas the second domain contains described. 11 Factor-dependent AML cell lines HEL, KG-1, KGthree zinc fingers and binds to the sequence GAAGATGAG.
1a, HL60 and U937 were maintained in RMPI 1640/5% FBS EVI-1 protein may act as either a weak transcriptional actias described. 9, 11 The acute promyelocytic leukemia cell line vator or a repressor in in vitro reporter gene systems. 5, 6 
NB4
18 was kindly provided by Dr Michel Lanotte, Inserm Hos-EVI-1 expression was not detected in normal marrow or perpital, St Louis, Paris, France. Karyotypes of NB4 and primary ipheral blood, but is expressed in a subset of acute myelogen-APL cells were performed as previously described. 9, 10 The NB4 cells had a modal chromosome number of 70-77 with der(15)t (15;17) , der(10)t (10;19) , dic (9;19) , del(7)q31 and transcript detected using RT-PCR. 19 Peripheral blood and bone marrow specimens Bone marrow or blood from acute promyelocytic leukemia patients were obtained as excess pathologic material. The diagnosis of acute promyelocytic leukemia was verified by morphology, histochemical staining, karyotype and RT-PCR for the PML-RAR␣ fusion transcript. 19, 20 Leukemia specimens were separated on Ficoll-Hypaque as described 21 and frozen in 10% DMSO/90% FBS prior to study.
Materials
All-trans retinoic acid (ATRA) and 13-cis retinoic acid were obtained from Sigma Chemicals (St Louis, MO, USA). 9-cis retinoic acid was kindly provided by Dr Ethan Dmitrovsky, Memorial/Sloan-Kettering Cancer Center, New York, NY, USA. Retinoid solutions were made fresh for each experiment and shielded from light. All experiments were performed under low-light conditions. rh-GM-CSF was kindly provided by Dr Stephen Gillis, Immunex Incorporation, Seattle, WA, USA.
ATRA-induced differentiation of NB4 promyelocytic leukemia cells
To induce differentiation of NB4 cells, cells were exposed to 0.5 or 1 m ATRA dissolved in DMSO or an equivalent amount of DMSO for 1 to 7 days. NB4 cells were also exposed to 1 m 13-cis retinoic acid or 1 m 9-cis retinoic acid for 5 days. Differentiation was assessed by expression of the CD11b or CD16 antigens detected by flow cytometry and by TPAinducible, NBT dye reduction. 22 In some experiments, NB4 cells were exposed to 2 mm N,NЈ-hexamethylene-bis-acetamide (HMBA) for 5 days and differentiation assessed. NB4 cells were also exposed to 1 m ATRA or FBS for 1 day, washed and replated at equal densities with FBS alone, 1 m ATRA, or 2 mm HMBA as described by others 23 and differentiation assessed at the 5th or 7th day of culture.
Detection of EVI-1 RNA RNA was extracted from cell lines and primary specimens as described.
9,10 EVI-1 RNA was detected by RNA polymerase Figure 1 (a) EVI-1 expression detected by RT PCR in patients with acute promyelocytic leukemia. M, mock reaction; H, HL60 negative control RNA; N, NB4 APL cell line at time zero; N*, NB4 cell line after culture for 7 days with ATRA; lanes 1-5, APL patients. *Patient 2 indicates specimen was obtained during ATRA therapy; U, UCSD/AML1 positive control RNA. In most patients, alternative splicing gives rise to two products. Results in patient 3 showed two products in some assays and a single prominent band in others. The product was verified as EVI-1 RNA by Southern blotting. (b) EVI-1 expression detected by RT-PCR during all-trans retinoic acid (ATRA) therapy of a patient with acute promyelocytic leukemia. Lanes 1, 7 100-bp markers; lanes 2, 8 mock reactions; lanes 3, 9 pre-treatment bone marrow; lanes 4, 10 marrow after 4 weeks ATRA therapy; lanes 5, 11 after 5 weeks ATRA therapy prior to achieving remission; lanes 6, 12 EVI-1 positive control RNA. chain reaction as described in detail previously and visualized days with ATRA were assayed for EVI-1 transcripts by RNase protection as described. 9 We showed previously that RNase using ethidium bromide-stained, agarose gels. 9, 10, 24 Primer sets spanning sequences from bp 223 to 702 containing 45 protection was approximately 300× less sensitive than RT-PCR for detecting EVI-1 RNA. 9 To assess effects of cycloheximide bp of 5Ј flanking and 434 bp of coding sequence (5Ј primer set; 5Ј primer 5Ј-GTACTCGAGAGTAGTTGCAGACATTGCor actinomycin D on ATRA-induced EVI-1 RNA, NB4 cells were incubated with 1 m ATRA for 5 days and then cultured 3Ј, 3Ј primer 5Ј-GTCCTCGAGTTGCTAGGGTCGGTGAAA-ACC-3Ј) and bp 2110 to 2390 (3Ј primer set; 5Ј primer, with 10 g/ml cycloheximide or 10 g/ml actinomycin D for 1-4 h. At various times, RNA was extracted and quantitated 5Ј-ACTGACTGTAAGAGCTCACTGGCCTCAGGT-3Ј, 3Ј primer 5Ј-AGCAACGTCGAATCAAGACCTGCTTGAGAT-3Ј) of by PCR or RNase protection. 9, 12 the coding sequence were employed. 9 The 3Ј primers detect alternatively spliced transcripts and give rise to two bands in most preparations as described in detail previously. 9, 10 In
Expression of PML-RAR␣ in U937 cells some experiments, the same cDNA yields only a single band in PCR reactions. These products have been previously veriHuman PML-RAR␣ cDNA (kindly provided by Dr Ethan Dmitrovsky) was cloned into pBK-CMV vector (Stratagene, La fied as representing EVI-1 RNA. 9, 24 Primers detecting histone or GAPDH RNA were used as controls. 9, 10 Because control Jolla, CA, USA) to create a pBK/PML-RAR␣ plasmid. The pBK/PML-RAR␣ plasmid was electroporated into U937 cells. transcripts are more abundant than EVI-1 RNA, RT-PCR for these genes was performed using 50% of the primer concen-U937 cells were resuspended at 2-4 × 10 7 cells/ml in serumfree medium. Cell suspension 0.5 ml was placed into a 0.4 cm trations added for EVI-1 reactions. RNA from the UCSD/AML1 or HEL cell lines 10, 12 served as positive controls and RNA from electroporation cuvette (BioRad, Hercules, CA, USA) and 10 g pBK/PML-RAR␣ plasmid added. Cells and plasmid were the HL60 cell line as a negative control for EVI-1 RNA. 9, 10 The identity of the EVI-1 PCR products was verified by proincubated for 10 min on ice prior to electroporation at 960 F, 400 V (BioRad Gene Pulsar). The cuvettes were incubated on bing Southern blots of agarose gels with end-labeled oligonucleotides internal to the priming sequences as described in ice for 10 min 48 h after transfection, 800 g/ml of G418 were added to select neomycin-resistant cells. Selected, neo-resistdetail previously.
9,10,24 Both 3Ј EVI-1 RT-PCR products from all-trans retinoic acid-induced NB4 cells were also subject to ant cells were checked for PML-RAR␣ expression by RT-PCR. Primers used in the RT-PCR reactions are primer 1, 5Ј-automated sequencing 9 and were consistent with the EVI-1 cDNA. 25 Serial dilutions of RNA from NB4 cells treated for 7 CTGGTGCAGAGGATGAAGTG-3Ј (PML cDNA bases 1074-ATRA were obtained and were advanced at intervals of 1-2 weeks into serially higher ATRA concentrations up to 10 m. These cells were maintained in ATRA for Ͼ12 weeks. Using sublines resistant to 1-10 m ATRA derived from two separate experiments, cells were removed from ATRA for periods of 4-8 weeks and then tested for EVI-1 RNA expression by RT-PCR, HMBA-induced differentiation, and ATRA-induced differentiation as described above. Induction of programmed cell death (apopotosis) in HMBA-and ATRA-treated cells was assessed using flow cytometry to detect TdT-mediated, dUTP incorporation into damaged DNA as described in detail previously.
Statistics
Differences between various treatment conditions were compared using Student's t-test for paired observations.
Results

EVI-1 expression in patients with APL
In a recent study, we detected EVI-1 expression by AML and MDS patients without 3q26 translocations. 9 Two of these AML patients had FAB M3 (APL), although only one had the characteristic t(15;17). 9 To explore this finding further, cells from 11 additional patients with APL were studied. Five of nine cases studied prior to therapy were positive for EVI-1 RNA (Figure 1a, b) . In re-evaluating EVI-1 negative cases, we noted that two patients initially negative for EVI-1 RNA by PCR became positive within 2-5 weeks when treated with ATRA before entering complete remission (Figure 1b ). EVI-1 RNA was also detected in one patient after 4 and 5 weeks of ATRA therapy (Figure 1b) . EVI-1 expression was absent in two APL patients in complete remission (Figure 1c ). EVI-1 RNA was
Figure 3
Expression of EVI-1 during ATRA and HMBA-induced detected in two of four APL patients studied at relapse from differentiation of NB4 cells. NB4 cells were grown for 24 h in FBS or FBS + 1 m ATRA, washed, and then cultured for 4 days in FBS, ATRA chemotherapy or ATRA treatment. These findings suggest or 2 mm HMBA (see Table 1 ). Top, EVI-1 RNA PCR; bottom, GAPDH.
ATRA induced EVI-1 expression during in vivo differentiation
Results shown are for cells harvested at the 5th day of culture. Lane of some APL cells. treated with 1 m ATRA for 1 day. EVI-1 RNA was not detected at earlier time points (Figure 2a) . Expression appeared to increase over time and was maximal at 5-7 days 1094), primer 2 5Ј-CCATAGTGGTAGCCGTGAGGA-3Ј (RAR␣ cDNA bases 404-424). 19 The resulting PML-RAR␣ (Figure 2a ). Similar to all other studies we previously performed using hemopoietic and non-hemopoietic target cells expressing U937 cells were assessed for EVI-1 expression before and 5-7 days after treatment with 1 m ATRA by RTand these PCR procedures, 9,10,24 the identity of the EVI-1 PCR products was verified by probing Southern blots of PCR pro-PCR described above.
ducts from NB4 cells treated for 5 days with ATRA; by the concurrent presence of the 5Ј EVI-1 RT-PCR product; and by RNase protection (Figure 2b ). Both EVI-1 3Ј PCR products
Derivation of ATRA-resistant NB4 cells from ATRA-treated NB4 cells were also sequenced and were identical to those in UCSD/AML1 cells 10 and HEC1b carciTo derive ATRA-resistant NB4 cells, cells were cultured in 0.5 m ATRA and serially passaged in fresh medium and noma. 25 Titration of RNA from NB4 cells treated for 7 days with 1 m ATRA using RNase protection and RNA from ATRA every 3-5 days or when cultures reached a cell density of 1 × 10 6 /ml. After 10-15 days, cell proliferating in 0.5 m UCSD/AML1 cells which express EVI-1 due to a 3q26 translo- containing FBS, FBS/ATRA or FBS/HMBA. NB4 cells exposed to ATRA for 1 day then cultured in FBS underwent some differInduction of EVI-1 RNA by ATRA at 1 day was not blocked by 10 g/ml cycloheximide but was blocked as expected by entiation (Table 1 ). Differentiation as assessed by NBT dye reduction was significantly greater after 5 days compared to 10 g/ml actinomycin-D. In other studies, EVI-1 RNA was also induced in NB4 cells by 1 m 13 cis-retinoic acid or 9-cis 1 day ATRA treatment followed by culture with FBS for 4 days (P = 0.04). retinoic acid (two experiments). The half-life of ATRA-induced EVI-1 RNA was estimated by treating NB4 cells exposed to Prior studies 23 showed 0.5-2 mm HMBA alone did not induce NB4 cell differentiation, but induced differentiation ATRA for 5 days with actinomycin-D for 1-4 h and was 2.5 h, essentially identical to results obtained in UCSD/AML1 leukeafter 1 day or 30 min of 'priming' with ATRA. As shown in Table 1 , when cells were grown in medium for 1 day and mia and HEC1b endometrial carcinoma cells. 12 Thus, ATRA induction of EVI-1 DNA appeared to require new RNA, but transferred to HMBA (Table 1) or cultured with HMBA alone for 5 days (not shown, two experiments), NB4 cells did not not protein, synthesis and survival of EVI-1 transcripts was identical to that in other cells.
differentiate. In contrast, when NB4 cells were incubated for 1 day with ATRA, and then transferred to HMBA, extensive AML leukemia cell lines HL60, U937, KG-1, and AML-193 cells were exposed to 1 m ATRA for 5 days, and RNA from differentiation occurred. CD11b expression was significantly higher after 5 days ATRA (P = 0.006) and 1 day ATRA + 4 these lines assessed for EVI-1 transcripts using RNA PCR. No EVI-1 transcripts were detected. HL60 cells underwent differdays HMBA (P Ͻ 0.02) treatment than with 1 day ATRA followed by culture with FBS. Cultures continuously exposed to entiation in response to ATRA and increased CD11b expression after 5 days from 8 to 88% positive cells (two ATRA for 5 days showed significant growth suppression at day 3 (Control 1.37 ± 0.09 × 10 6 cells/ml, mean ± s.e.; ATRA 0.74 experiments). Thus, ATRA did not induce EVI-1 expression in other AML cell lines, including HL60 cells which undergo Ϯ 0.12 × 10 6 /ml, P Ͻ 0.05) and day 5 ( Table 1 , P Ͻ 0.01). Cells exposed for 1 day to ATRA and then to HMBA also extensive, ATRA-induced myeloid differentiation.
showed significant growth inhibition at day 3 (ATRA/HMBA 0.69 ± 0.17 × 10 6 cells/ml, P Ͻ 0.05) and day 5 ( Table 1 , P Ͻ 0.01). Growth inhibition after culture for 1 day with ATRA Continuous EVI-1 expression is not required for NB4 differentiation and then 4 days with HMBA was significantly greater than 5 days culture with ATRA (Table 1, P Ͻ 0.01).
The effects of these incubation conditions on EVI-1 As expected from prior studies, 18 ,23 ATRA treatment for 4-5 days induced differentiation of NB4 cells (Table 1) , indicating expression are shown in Table 1 and Figures 3 and 6 . When NB4 cells were incubated in ATRA for 1 day and then transthat EVI-1 expression did not prevent ATRA-induced APL dif- ferred to medium with FBS, EVI-1 RNA was present at 1 day cultured in 0.5 m ATRA. Figure 5 shows results representative of three experiments. In response to ATRA treatment, NB4 but not observed at 5 day (Figure 3 ) despite some differentiation (Table 1) . Time course studies showed EVI-1 RNA was cells initially demonstrated marked growth inhibition (Figure 5a and b) and extensive programmed cell death not detected 1 day after removing cells from ATRA. Similarly, when NB4 cells were incubated for 1 day with ATRA and ( Figure 5d ). Differentiation markers were also induced ( Figure 5c ). However, as cells were cultured for longer times, transferred to cultures containing HMBA, EVI-1 expression was not observed at 3 days (not shown), 5 days or 7 days cell growth resumed, markers of differentiation disappeared ( Figure 5c ) and evidence of programmed cell death fell to (Table 1, Figures 3 and 6) . Thus, EVI-1 expression during short-term ATRA treatment appeared dependent on continued basal (untreated cell) levels (Figure 5d ). In contrast, when cells were cultured for 24 h in ATRA and then transferred to 2 mm presence of ATRA, but continuous expression of EVI-1 was not required for NB4 cell differentiation when cells were HMBA, growth inhibition, differentiation, and programmed cell death occurred, but no resistant cells emerged (Figure 5a Expression of PML-RAR␣ alone is not sufficient for ATRA-induced EVI-1 expression including the der(15)t(15:17) and continued to express PML-RAR␣ RNA detected by PCR. Cells maintained in 1 or 3 m ATRA showed undifferentiated morphology and basal levels In extensive previous studies by ourselves 9, 10 and others, 8 normal bone marrow and cord blood mononuclear cells did not of differentiation similar to untreated, parent NB4 cells and were induced only slightly by HMBA to express CD11b (3 m contain detectable EVI-1 RNA. Thus, the response of NB4 and APL promyelocytes to ATRA initially appeared to be unique. resistant cells = control 15 ± 7%; HMBA treated, 45 ± 7%; means Ϯ s.e. not significant, three experiments, P Ͻ 0.02) or Because of this finding, we considered the possibility that ATRA-induced, EVI-1 expression represented a response to the NBT dye reduction (0% control; 6 ± 4% HMBA, three experiments). Thus, ATRA-resistant NB4 cells maintained in abnormal, PML-RAR␣ fusion gene present in APL but absent from normal promyelocytes and other leukemias. To evaluate ATRA lacked differentiation markers, and resulting sublines differentiated poorly in response to HMBA. this possibility, the PML-RAR␣ RNA was expressed in U937 histiocytic lymphoma cells. Figure 4a shows RNA PCR results ATRA-resistant cells derived from two such experiments were studied for EVI-1 RNA expression. Consistent with results from G418-resistant U937 cells expressing the PML-RAR␣ fusion gene. Control and PML-RAR␣ expressing U937 cells shown above, ATRA initially induced differentiation and EVI-1 expression detected by RNA/PCR which was lost when cells were treated with 1 m ATRA for 5 or 7 days and EVI-1 RNA expression assessed by RNA PCR. As shown in Figure 4b , a were transferred to HMBA (Figure 6a ). NB4 cells derived by continuous culture in ATRA continued to express EVI-1 faint signal from EVI-1 PCR was obtained in PML-RAR␣ expressing U937 cells which appeared to be absent from condespite the absence of differentiation (Figure 6a) . Surprisingly, in contrast to cells treated for 1-7 days and then removed from trol cells. However, this signal did not increase even with increased PCR cycles from 30 to 40 and was not considered ATRA (Table 1) , ATRA-resistant cells removed from ATRA for у4 weeks also continued to express EVI-1 RNA detected by specific (three studies). We also treated PML-RAR␣ expressing U937 cells with 10 m ATRA or vitamin D 3 for 7 days, but PCR (Figure 6b ). Thus, selection of ATRA-resistant cells recapitulated observations in some APL patients resulting in EVI-1 expression was not induced. Thus, under these conditions, PML-RAR␣ expression alone was not sufficient to con-APL cells with constitutive, non-ATRA-dependent, EVI-1 expression. fer competence for ATRA-induced, EVI-1 expression.
EVI-1 is expressed by some ATRA-resistant APL cells Discussion EVI-1 is a member of the large, Zn finger DNA binding gene Two of four APL patients studied at relapse expressed EVI-1 RNA, suggesting EVI-1 expression might be affected by prior family. 3, 27 It has been estimated these genes constitute Ͼ1% of some human chromosomes. 4 3, 4 Zn finger genes such as EVI-1 are thought to be transcription factors or to regulate ies using the APL PML-RAR␣-expressing U937 cells indicate expression of this abnormal fusion gene alone does not make transcription induced by other genes. 5, 13 Zn finger genes, including EVI-1, 28 are also frequent participants in the abnorcells competent for ATRA-induced EVI-1 expression. This does not exclude the possibility that more complex interactions mal fusion genes generated by chromosome translocations in human acute leukemias. 29 between PML-RAR␣ and other retinoic acid receptors regulate EVI-1. The EVI-1 RNA is expressed in mononuclear cells from acute leukemias with translocations involving 3q26 7, 8, 12 and Similar to studies by others, ATRA-resistant NB4 cells were consistently obtained by selection in escalating concentrations in cells from some AML and myelodysplasia patients without such translocations, 9 but was not detected in normal marof ATRA and were refractory to differentiation induction.
30
This finding appears similar to emergence of ATRA resistance row. 8, 9 As noted, above, enforced EVI-1 expression in murine leukemia and normal murine marrow cells blocked erythroin ATRA-treated, APL patients. In contrast to results obtained in short-term cultures, ATRA-resistant NB4 cells constitutively cyte or granulocyte differentiation. 15 However, very recent studies suggest the level of EVI-1 RNA may be a critical deterexpressed EVI-1 and this expression persisted for at least several weeks in the absence of ATRA. This finding was mirrored minant of whether murine leukemia cells differentiate or are blocked from G-CSF-induced differentiation. 6 EVI-1 in two of four relapsed APL patients who expressed EVI-1 RNA without in vivo or in vitro ATRA treatment. expression associated with acquired 3q26 translocations has also been observed as a transforming event in chronic myelo-ATRA treatment of APL cells, such as NB4, induced EVI-1 expression may represent a recapitulation of a normal differgenous leukemia, suggesting it may block differentiation in this setting. 10 These studies indicate EVI-1 is abnormally entiation program in promyelocytes rather than an abnormal response to the PML-RAR␣ protein.
In APL patients undergoexpressed in myeloid leukemias and suggest that increased EVI-1 expression or the action of EVI-1 fusion genes play ing ATRA therapy, EVI-1 expression after treatment could be due to the presence of differentiating APL or normal promyimportant roles in pathogenesis or progression of acute leukemias and myelodysplasias.
elocytes. Consistent with this interpretation, preliminary studies by ourselves 31 and others 32 showed EVI-1 RNA is detected The normal functions and regulation of the EVI-1 gene in hematopoietic cells remain unknown. EVI-1 acts as a tranin normal CD34-positive enriched cells before and after shortterm cytokine stimulation, suggesting a more general role for scription factor when bound to a consensus sequence of GACAAGATAAGATAAN1-28 CTCATCTTC. 5 EVI-1 protein EVI-1 in regulating hematopoietic cell proliferation, migration or differentiation. also binds genomic sequences containing GATA motifs 6, 15 and binds to and antagonizes transcriptional activation by Findings in the current studies and preliminary data with normal cells 31, 32 indicate the role(s) of EVI-1 in normal myelo-GATA-1. 6, 15 However, very recent studies suggest that EVI-1's affinity for genomic GATA sequences is low and that in vivo poiesis, acute leukemias and myelodysplasia are likely to be complex. Other Zn finger genes, such as GATA-1, show combinding to GATA promoter motifs is unlikely to occur in intact cells. 15 Thus, the roles and mechanisms of action of EVI-1 plex effects on normal gene expression resulting in transcription stimulation; 33 facilitated effects of other transcription facremain unknown despite evidence suggesting it is prominently involved in some experimental and human leukemias and tors; 34 or transcription repression depending on the context of GATA-1 expression. 35 EVI-1 could play a dual role in regmyelodysplasias.
Factors regulating EVI-1 expression in normal and leukemia ulating differentiation, by competing with a subset of GATA-1 building genes blocking erythroid cell differentiation, and by cells with or without 3q26 translocations are also unknown. In previous studies, bioactive compounds such as phorbol binding to some EVI-1 regulated genes promoting granulocyte differentiation. This response may depend, in part, on the level esters and cytokines did not specifically regulate UCSD/AML1 cell line EVI-1 expression when compared to a 'housekeeping' of EVI-1 expression. 6 In the current studies, the pattern of EVI-1 expression in APL and preliminary data in normal cells 31, 36 gene such as actin. 12 ATRA was not examined in these studies, but does not alter EVI-1 expression in UCSD/AML1 cells (R suggest it may promote granulocyte differentiation, and experimental studies indicate it can block erythroid differenTaetle et al, unpublished). Based on the time course of response to ATRA and failure of cycloheximide to block EVItiation. 15 Further studies using normal progenitor cells and EVI-1 gene transfer to the NB4 cell line are being performed 1 induction, the present studies using NB4 cells suggest ATRA regulates EVI-1 transcription in APL cells, representing the first to address these questions. example of EVI-1 regulation in leukemia by a biologically active agent.
